Results 51 to 60 of about 249 (106)
Additional file 1 of Clinical effects of a selective urate reabsorption inhibitor dotinurad in patients with hyperuricemia and treated hypertension: a multicenter, prospective, exploratory study (DIANA)
, 2023 Additional file 1: Table S1.Isao Taguchi (3472403), Itaru Hisauchi (16560137), Toshiaki Kadokami (3472397), Hiroshi Hongo (3026754), Tetsuya Ishikawa (653995), Shusuke Yagi (220199), Hisako Yoshida (685101), Michio Shimabukuro (656310), Koichi Node (384063), Masataka Sata (327827), Atsushi Tanaka (40313) +10 morecore +1 more sourceAdditional file 4 of Clinical effects of a selective urate reabsorption inhibitor dotinurad in patients with hyperuricemia and treated hypertension: a multicenter, prospective, exploratory study (DIANA)
, 2023 Additional file 4: Table S3.Isao Taguchi (3472403), Itaru Hisauchi (16560137), Toshiaki Kadokami (3472397), Hiroshi Hongo (3026754), Tetsuya Ishikawa (653995), Shusuke Yagi (220199), Hisako Yoshida (685101), Michio Shimabukuro (656310), Koichi Node (384063), Masataka Sata (327827), Atsushi Tanaka (40313) +10 morecore +1 more sourceAdditional file 3 of Clinical effects of a selective urate reabsorption inhibitor dotinurad in patients with hyperuricemia and treated hypertension: a multicenter, prospective, exploratory study (DIANA)
, 2023 Additional file 3: Table S2.Isao Taguchi (3472403), Itaru Hisauchi (16560137), Toshiaki Kadokami (3472397), Hiroshi Hongo (3026754), Tetsuya Ishikawa (653995), Shusuke Yagi (220199), Hisako Yoshida (685101), Michio Shimabukuro (656310), Koichi Node (384063), Masataka Sata (327827), Atsushi Tanaka (40313) +10 morecore +1 more sourcePreformulation Study
for Seven Solid Forms of Dotinurad
Dotinurad, a novel selective urate reabsorption inhibitor,
was
studied for preformulation beneficiation by supramolecular methods.
Two polymorphic forms (form I, form II), a monohydrate, and four solvates
were prepared and characterized by single-crystal Dier Shi (4832610), Jiyong Liu (1672381), Kaxi Yu (12133856), Shuna Liu (4824336), Xiurong Hu (3369356) +4 morecore +1 more sourceAdditional file 7 of Clinical effects of a selective urate reabsorption inhibitor dotinurad in patients with hyperuricemia and treated hypertension: a multicenter, prospective, exploratory study (DIANA)
, 2023 Additional file 7: Text S1.Isao Taguchi (3472403), Itaru Hisauchi (16560137), Toshiaki Kadokami (3472397), Hiroshi Hongo (3026754), Tetsuya Ishikawa (653995), Shusuke Yagi (220199), Hisako Yoshida (685101), Michio Shimabukuro (656310), Koichi Node (384063), Masataka Sata (327827), Atsushi Tanaka (40313) +10 morecore +1 more sourceAdditional file 6 of Clinical effects of a selective urate reabsorption inhibitor dotinurad in patients with hyperuricemia and treated hypertension: a multicenter, prospective, exploratory study (DIANA)
, 2023 Additional file 6: Table S5.Isao Taguchi (3472403), Itaru Hisauchi (16560137), Toshiaki Kadokami (3472397), Hiroshi Hongo (3026754), Tetsuya Ishikawa (653995), Shusuke Yagi (220199), Hisako Yoshida (685101), Michio Shimabukuro (656310), Koichi Node (384063), Masataka Sata (327827), Atsushi Tanaka (40313) +10 morecore +1 more sourceTherapeutic Effects of Dotinurad and Febuxostat in Chronic Kidney Disease Patients with Hyperuricemia [PDF]
慢性腎臓病（CKD）患者は血清尿酸値が高いことが多く，高尿酸血症は腎不全や脳心血管病の危険因子となる．腎機能が低下している場合，高尿酸血症治療薬として尿酸排泄促進薬は効果的ではなく，尿酸生成抑制薬であるアロプリノール（ALP）も副作用に注意を要するが，フェブキソスタット（FBX）などの非プリン系キサンチンオキシダーゼ阻害薬が腎不全患者にも用いられるようになり，選択的尿酸再吸収阻害薬であるドチヌラド（DTN）も導入されている．本研究では ...Tojo, Akihiro, Rai, Tatemitsu, Yokoyama, Shohei, 横山, 翔平, 石光, 俊彦, 高橋, 知里, 本多, 勇晴, 藤乘, 嗣泰, Takahashi, Chisato, Honda, Takeaki, Ishimitsu, Toshihiko, 賴, 建光 +11 morecore +1 more source
